Brief: Aridis Pharmaceuticals Announces Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against Omicron,Other COVID-19 Variants
21/12/2021 09:16
Dec 21 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS PHARMACEUTICALS ANNOUNCES A PAN-CORONAVIRUS
MONOCLONAL
ANTIBODY COCKTAIL THAT RETAINS EFFECTIVENESS AGAINST OMICRON
VARIANT, OTHER COVID-19 VARIANTS, SARS, MERS, AND COMMON COLD
HUMAN CORONAVIRUSES
* VIRAL NEUTRALIZATION AND ANIMAL INFECTION MODELS SUPPORT
BROAD
PROPHYLAXIS,THERAPEUTIC EFFICACY OF AR-701 AGAINST
SARS-COV-2,SARS
Source text for Eikon: ID:nPn4LWQDma
Further company coverage: ARDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music